Navigation Links
Advance in regenerative medicine could make reprogrammed cells safer while improving their function
Date:8/1/2013

NEW YORK (Aug. 1, 2013) -- The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.

The researchers' study, published in today's issue of the journal Nature, found that an enzyme, activation-induced cytidine deaminase (AID), helps in the process that changes an adult human cell into an induced pluripotent stem cell (iPS cell). These iPS cells can then be developed into any kind of cell needed to therapeutically restore tissues and organs.

The finding settles an ongoing controversy regarding use of AID to reprogram cells, says the study's senior investigator, Dr. Todd Evans, vice chair for research and professor of cell and developmental biology in the Department of Surgery at Weill Cornell Medical College.

"The dispute was whether AID is required to make iPS cells, and we found that the enzyme does make reprogramming very efficient, although it is not absolutely necessary," says Dr. Evans, an internationally-recognized authority on regenerative medicine. "In fact, we plan to test if reprogramming iPS cells without AID may even be helpful."

One reason is that AID can cause genetic mutations that can lead to cancer. AID is best known as a master regulator of antibody diversity in B cells, and in order to create varied types of beneficial antibodies, it routinely mutates antibody genes. But sometimes the process goes awry, resulting in development of B cell lymphoma, Dr. Evans says. "That leads us to believe that if you can reprogram cells without AID, it could reduce risk of potential mutations, and thus be safer."

iPS Cells Without AID Remember What They Once Were

In order to push a cell, such as a fibroblast, to revert to an iPS cell, the epigenetic "markers" that define an adult cell must be removed.
'/>"/>

Contact: John Rodgers
jdr2001@med.cornell.edu
646-317-7401
Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
2. MARC travel awards announced for the AAI 2013 Advanced Course in Immunology Meeting
3. Advance Research Associates Partners With MedNet Solutions
4. New sickle cell anemia therapy advances to Phase II clinical trials
5. OHSU scientists advance understanding of brain receptor; may help fight neurological disorders
6. Engineered stem cell advance points toward treatment for ALS
7. NSF approves planning grant for Center for Advanced Research in Drying
8. New advances in the management of patients with cirrhosis
9. Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting
10. Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR
11. Research advances therapy to protect against dengue virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2014)... and fungi can evade treatment by acquiring mutations in ... permanent mutations were once thought to be the only ... study has shown that microorganisms can use a temporary ... to gain the benefits of drug resistance without the ... a fungus called Mucor circinelloides, it is likely to ...
(Date:7/27/2014)... at Barts Cancer Institute have found that targeting a ... more effective, according to research published in Nature ... part of Queen Mary University of London, have found ... the body to repair itself after chemotherapy or radiotherapy, ... researchers removed FAK from blood vessels that grew in ...
(Date:7/27/2014)... 18,000 patients, scientists have identified more than two ... including six that had not been previously reported. ... was partially funded by the National Institutes of ... NIH laboratories. , "Unraveling the genetic underpinnings of ... involved in this complex disease, and hopefully, may ...
Breaking Biology News(10 mins):Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3New drug target can break down cancer's barrier against treatment 2NIH scientists find 6 new genetic risk factors for Parkinson's 2
... laser laboratory operational later this year, he will use ... bonds like a stringed musical instrument. Tokmakoff, the ... at the University of Chicago in January to tackle ... vibrational spectroscopy methods that he has developed. "He ...
... Cognitive impairments are disabling for individuals with schizophrenia, ... affect a wide range of cognition, including memory, ... appear in the earliest stages of the disease ... Scientists are exploring a variety of strategies ...
... 2013 Shiner Beers, the popular Texas craft brew, will ... for Diabetes Research at the Translational Genomics Research Institute (TGen). ... kick off on Wednesday, March 13, at the Hotel San ... Conferences & Festivals. The noon-8 p.m. event, themed after ...
Cached Biology News:Watery research theme to flow through new Tokmakoff lab 2Watery research theme to flow through new Tokmakoff lab 3Tickling the brain with magnetic stimulation improves memory in schizophrenia 2Shiner Beers launches nationwide support of TGen diabetes studies 2
(Date:7/28/2014)... DC (PRWEB) July 28, 2014 It’s a ... GI Bill benefits to further their post-secondary education are failing ... a study released this year. And according to an analysis ... this shortfall is veteran students’ uninformed choice of college majors, ... The details of the study: Some 51.7 percent of post-9/11 ...
(Date:7/28/2014)... 28, 2014 Research and Markets has ... Market 2014-2018" report to their offering. ... is a technique used to determine the size of a ... is crucial to analyze the size of particles as it ... analysis is performed to determine the behavior and nature of ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... According to a new market report ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast, ... estimated at USD 161,056.5 million in 2014 and is ... 2014 to 2020, to reach an estimated value of ... market is witnessing a significant growth due to the ...
Breaking Biology Technology:Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Particle Size Analysis Market 2014-2018 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
... /PRNewswire-Asia-FirstCall/  - China Cord Blood Corporation (NYSE: ... largest cord blood banking operator in China, today announced ... which allowed warrant holders to receive one ordinary share ... ordinary shares, equivalent to 2.2% of shares outstanding as ...
... BioTrends Research Group, Inc. finds that with ... (DMA) for the treatment of multiple sclerosis (MS), neurologists anticipate ... month after the launch of Gilenya, trial and uptake of ... to be tempered due to the perception that Extavia is ...
... December 9, 2010 Scientists from Pacific Biosciences of ... successfully employed single molecule, real-time (SMRT) DNA sequencing technology ... deadly cholera epidemic in Haiti. Published Thursday in ... results provide the first whole genome sequence analysis and ...
Cached Biology Technology:China Cord Blood Corporation Announces Completion of Warrant Exchange 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 3Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 2Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 3
... Dithiothreitol DTT White solid.. ... disulfides to thiols, so reaction is "driven" to ... not contain waxy surfactant found in many other ... pentobarbitol. Purity: ≥97% by titration. ...
... This kit is designed for easy transformation ... protocol allows for successful transformation simply by ... reagents with cultured yeast cells. No complicated ... are required. The kit is particularly well ...
... for easy transformation of the budding yeast, ... transformation simply by mixing a plasmid DNA ... cells. No complicated steps, such as centrifugation ... is particularly well suited for high-throughput transformation ...
... pro balance increases your lab productivity and allows ... and regulatory compliance. Move ahead beyond traditional paper-based ... data system. *Instruments supported: ... MX, UMX, AG, XS, XP, PR, SR, PG-S, ...
Biology Products: